tooluniverse-binder-discovery by mims-harvard/tooluniverse
npx skills add https://github.com/mims-harvard/tooluniverse --skill tooluniverse-binder-discovery利用 60 多种 ToolUniverse 工具,通过成药性评估、已知配体挖掘、相似性扩展、ADMET 过滤和合成可行性分析,系统性地发现新型小分子结合物。
关键原则:
请勿向用户展示搜索过程或工具输出。相反:
* 文件名:`[TARGET]_binder_discovery_report.md`
* 使用模板中的所有章节标题进行初始化(参见 REPORT_TEMPLATE.md)
* 在每个章节中添加占位符文本:`[研究中...]`
2. 逐步更新报告 - 随着数据收集:
* 立即用发现更新每个章节
* 用户看到的是报告的增长,而不是搜索过程
广告位招租
在这里展示您的产品或服务
触达数万 AI 开发者,精准高效
3. 输出单独的数据文件:
* `[TARGET]_candidate_compounds.csv` \- 带有 SMILES 和分数的优先化合物
* `[TARGET]_bibliography.json` \- 文献参考文献(可选)
每条信息必须包含其来源:
*来源:通过 `ChEMBL_get_target_activities` 获取的 ChEMBL(CHEMBL203)*
*来源:通过 `get_protein_metadata_by_pdb_id` 获取的 PDB(1M17)*
*来源:通过 `ADMETAI_predict_toxicity` 获取的 ADMET-AI*
*来源:通过 `NvidiaNIM_alphafold2` 获取的 NVIDIA NIM(pLDDT:90.94)*
Phase 0: 工具验证(检查参数名称)
|
Phase 1: 靶点验证
|- 1.1 解析标识符(UniProt、Ensembl、ChEMBL 靶点 ID)
|- 1.2 评估成药性/可靶向性
| +- 1.2a GPCRdb 集成(针对 GPCR 靶点)
| +- 1.2.5 检查治疗性抗体(Thera-SAbDab)
|- 1.3 识别结合位点
+- 1.4 预测结构(NvidiaNIM_alphafold2/esmfold)
|
Phase 2: 已知配体挖掘
|- ChEMBL 生物活性数据
|- GtoPdb 相互作用
|- 化学探针(Open Targets)
|- BindingDB 亲和力数据(Ki/IC50/Kd)
|- PubChem BioAssay HTS 数据(筛选命中物)
+- 来自已知活性物的 SAR 分析
|
Phase 3: 结构分析
|- 含有配体的 PDB 结构
|- EMDB 冷冻电镜结构(针对膜靶点)
|- 结合口袋分析
+- 关键相互作用
|
Phase 3.5: 对接验证(NvidiaNIM_diffdock/boltz2)
|- 对接参考抑制剂
+- 验证结合口袋几何结构
|
Phase 4: 化合物扩展
|- 4.1-4.3 相似性/子结构搜索
+- 4.4 从头生成(NvidiaNIM_genmol/molmim)
|
Phase 5: ADMET 过滤
|- 物理化学性质(Lipinski、QED)
|- 生物利用度、毒性、CYP 相互作用
+- 结构警报(PAINS)
|
Phase 6: 候选物对接与优先级排序
|- 对接所有候选物(NvidiaNIM_diffdock/boltz2)
|- 按对接分数(40%)+ ADMET(30%)+ 相似性(20%)+ 新颖性(10%)评分
|- 评估合成可行性
+- 生成最终排序列表(前 20 名)
|
Phase 6.5: 文献证据
|- PubMed(同行评审的 SAR 研究)
|- EuropePMC 预印本(source='PPR')
+- OpenAlex 引用分析
|
Phase 7: 报告综合与交付
关键:在调用不熟悉的工具之前,验证工具参数。
tool_info = tu.tools.get_tool_info(tool_name="ChEMBL_get_target_activities")
| 工具 | 错误参数 | 正确参数 |
|---|---|---|
OpenTargets_* | ensembl_id | ensemblId(驼峰式) |
ChEMBL_get_target_activities | chembl_target_id | target_chembl_id |
ChEMBL_search_similar_molecules | smiles | molecule(接受 SMILES、ChEMBL ID 或名称) |
alphafold_get_prediction | uniprot | accession |
ADMETAI_* | smiles="..." | smiles=["..."](必须是列表) |
NvidiaNIM_alphafold2 | seq | sequence |
NvidiaNIM_genmol | smiles="C..." | smiles="C...[*{1-3}]..."(必须有掩码) |
NvidiaNIM_boltz2 | sequence="..." | polymers=[{"molecule_type": "protein", "sequence": "..."}] |
预先解析所有 ID 并存储以供下游查询:
1. UniProt_search(query=target_name, organism="human") -> UniProt 登录号
2. MyGene_query_genes(q=gene_symbol, species="human") -> Ensembl 基因 ID
3. ChEMBL_search_targets(query=target_name, organism="Homo sapiens") -> ChEMBL 靶点 ID
4. GtoPdb_get_targets(query=target_name) -> GtoPdb ID(如果是 GPCR/通道/酶)
使用多源三角测量:
OpenTargets_get_target_tractability_by_ensemblID(ensemblId) - 可靶向性分级DGIdb_get_gene_druggability(genes=[gene_symbol]) - 成药性类别OpenTargets_get_target_classes_by_ensemblID(ensemblId) - 靶点类别GPCRdb_get_protein + GPCRdb_get_ligands + GPCRdb_get_structuresTheraSAbDab_search_by_target(target=target_name)决策点:如果成药性 < 2 星,则警告用户存在挑战。
ChEMBL_search_binding_sites(target_chembl_id)get_binding_affinity_by_pdb_id(pdb_id) 用于共结晶配体InterPro_get_protein_domains(accession) 用于结构域架构需要 NVIDIA_API_KEY。两个选项:
NvidiaNIM_alphafold2(sequence, algorithm="mmseqs2") - 高精度,5-15 分钟NvidiaNIM_esmfold(sequence) - 快速(约 30 秒),最大 1024 个氨基酸始终报告 pLDDT 置信度分数(>=90 非常高,70-90 置信,<70 需谨慎)。
| 来源 | 工具 | 优势 |
|---|---|---|
| ChEMBL | ChEMBL_get_target_activities | 经过整理,SAR 就绪 |
| BindingDB | BindingDB_get_ligands_by_uniprot | 直接 Ki/Kd,文献链接 |
| GtoPdb | GtoPdb_get_target_interactions | 药理学重点(GPCRs、通道) |
| PubChem | PubChem_search_assays_by_target_gene | HTS 筛选,新型骨架 |
| Open Targets | OpenTargets_get_chemical_probes_by_target_ensemblID | 经过验证的探针 |
ChEMBL_get_moleculeBindingDB_get_targets_by_compoundPDB_search_similar_structures(query=uniprot, type="sequence") - 查找 PDB 条目get_protein_metadata_by_pdb_id(pdb_id) - 分辨率,方法get_binding_affinity_by_pdb_id(pdb_id) - 共结晶配体亲和力get_ligand_smiles_by_chem_comp_id(chem_comp_id) - 来自 PDB 的配体 SMILESemdb_search(query) - 冷冻电镜结构(GPCRs、离子通道首选)alphafold_get_prediction(accession) - AlphaFold DB 备用| 情况 | 工具 | 输入 |
|---|---|---|
| 有 PDB + SDF | NvidiaNIM_diffdock | protein=PDB, ligand=SDF, num_poses=10 |
| 有序列 + SMILES | NvidiaNIM_boltz2 | polymers=[...], ligands=[...] |
首先对接一个已知的参考抑制剂以验证结合口袋。
使用 3-5 个不同的活性物作为种子,相似性阈值 70-85%:
ChEMBL_search_similar_molecules(molecule=SMILES, similarity=70)PubChem_search_compounds_by_similarity(smiles, threshold=0.7)ChEMBL_search_substructure(smiles=core_scaffold)STITCH_get_chemical_protein_interactions(identifier=gene, species=9606)GenMol - 带有掩码区域的骨架跃迁:
NvidiaNIM_genmol(smiles="...core...[*{3-8}]...tail...[*{1-3}]...", num_molecules=100, temperature=2.0, scoring="QED")
掩码语法:[*{min-max}] 指定原子数量范围。
MolMIM - 受控的类似物生成:
NvidiaNIM_molmim(smi=reference_smiles, num_molecules=50, algorithm="CMA-ES")
按顺序应用过滤器(所有过滤器都接受 smiles=[list]):
| 步骤 | 工具 | 过滤标准 |
|---|---|---|
| 物理化学 | ADMETAI_predict_physicochemical_properties | Lipinski <= 1, QED > 0.3, MW 200-600 |
| 生物利用度 | ADMETAI_predict_bioavailability | 口服生物利用度 > 0.3 |
| 毒性 | ADMETAI_predict_toxicity | AMES < 0.5, hERG < 0.5, DILI < 0.5 |
| CYP | ADMETAI_predict_CYP_interactions | 标记 CYP3A4 抑制剂 |
| 警报 | ChEMBL_search_compound_structural_alerts | 无 PAINS |
在报告中包含一个过滤漏斗表,显示每个阶段的通过/失败计数。
| 维度 | 权重 | 来源 |
|---|---|---|
| 对接置信度 | 40% | NvidiaNIM_diffdock/boltz2 |
| ADMET 分数 | 30% | ADMETAI 预测 |
| 与已知活性物的相似性 | 20% | Tanimoto 系数 |
| 新颖性 | 10% | 不在 ChEMBL 中 + 新颖骨架奖励 |
| 等级 | 标准 |
|---|---|
| T0(4 星) | 对接分数 > 参考抑制剂 |
| T1(3 星) | 实验 IC50/Ki < 100 nM |
| T2(2 星) | 对接分数在参考值的 5% 以内 或 IC50 100-1000 nM |
| T3(1 星) | 与 T1 化合物相似度 > 80% |
| T4(0 星) | 相似度 70-80%,骨架匹配 |
| T5(空) | 生成的分子,ADMET 通过,无对接 |
提供前 20 名候选物,包含:排名、ID、SMILES、对接分数、ADMET 分数、总分、来源、证据等级。
PubMed_search_articles(query="[TARGET] inhibitor SAR") - 同行评审EuropePMC_search_articles(query, source="PPR") - 预印本(未经同行评审)openalex_search_works(query) - 引用分析Target ID: ChEMBL_search_targets -> GtoPdb_get_targets -> "Not in databases"
Druggability: OpenTargets tractability -> DGIdb druggability -> target class proxy
Bioactivity: ChEMBL -> BindingDB -> GtoPdb -> PubChem BioAssay -> "No data"
Structure: PDB -> EMDB (membrane) -> NvidiaNIM_alphafold2 -> NvidiaNIM_esmfold -> AlphaFold DB -> "None"
Similarity: ChEMBL similar -> PubChem similar -> "Search failed"
Docking: NvidiaNIM_diffdock -> NvidiaNIM_boltz2 -> similarity-based scoring
Generation: NvidiaNIM_genmol -> NvidiaNIM_molmim -> similarity search only
Literature: PubMed -> EuropePMC (preprints) -> OpenAlex
GPCR data: GPCRdb_get_protein -> GtoPdb_get_targets
| 工具 | 运行时间 | 备注 |
|---|---|---|
NvidiaNIM_alphafold2 | 5-15 分钟 | 异步,最大约 2000 个氨基酸 |
NvidiaNIM_esmfold | 约 30 秒 | 最大 1024 个氨基酸 |
NvidiaNIM_diffdock | 约 1-2 分钟 | 每个配体 |
NvidiaNIM_boltz2 | 约 2-5 分钟 | 端到端复合物 |
NvidiaNIM_genmol | 约 1-3 分钟 | 取决于 num_molecules |
NvidiaNIM_molmim | 约 1-2 分钟 | 紧密类似物生成 |
始终检查:import os; nvidia_available = bool(os.environ.get("NVIDIA_API_KEY"))
| 数据库 | 限制 | 策略 |
|---|---|---|
| ChEMBL | 约 10 次请求/秒 | 批量查询 |
| PubChem | 约 5 次请求/秒 | 批量端点 |
| ADMET-AI | 无严格限制 | 在列表中批量处理 SMILES |
| NVIDIA NIM | API 密钥配额 | 缓存结果 |
对于大型扩展(>500 个化合物):分批处理,每批 100 个,优先对接顶级候选物。
有关详细协议、示例和模板,请参阅:
| 文件 | 内容 |
|---|---|
| WORKFLOW_DETAILS.md | 分阶段程序、代码模式、筛选协议、备用链详情 |
| TOOLS_REFERENCE.md | 完整的工具参考,包含参数、使用示例和备用链 |
| REPORT_TEMPLATE.md | 报告文件模板、证据分级系统、章节格式示例 |
| EXAMPLES.md | 端到端工作流程示例(EGFR、新靶点、先导化合物优化、NVIDIA NIM) |
| CHECKLIST.md | 报告质量交付前验证清单 |
每周安装次数
146
仓库
GitHub 星标数
1.2K
首次出现
2026年2月7日
安全审计
安装于
gemini-cli137
codex137
opencode137
github-copilot134
kimi-cli129
amp129
Systematic discovery of novel small molecule binders using 60+ ToolUniverse tools across druggability assessment, known ligand mining, similarity expansion, ADMET filtering, and synthesis feasibility.
KEY PRINCIPLES :
DO NOT show search process or tool outputs to the user. Instead:
Create the report file FIRST - Before any data collection:
[TARGET]_binder_discovery_report.md[Researching...] in each sectionProgressively update the report - As you gather data:
Output separate data files :
[TARGET]_candidate_compounds.csv - Prioritized compounds with SMILES, scores[TARGET]_bibliography.json - Literature references (optional)Every piece of information MUST include its source:
*Source: ChEMBL via `ChEMBL_get_target_activities` (CHEMBL203)*
*Source: PDB via `get_protein_metadata_by_pdb_id` (1M17)*
*Source: ADMET-AI via `ADMETAI_predict_toxicity`*
*Source: NVIDIA NIM via `NvidiaNIM_alphafold2` (pLDDT: 90.94)*
Phase 0: Tool Verification (check parameter names)
|
Phase 1: Target Validation
|- 1.1 Resolve identifiers (UniProt, Ensembl, ChEMBL target ID)
|- 1.2 Assess druggability/tractability
| +- 1.2a GPCRdb integration (for GPCR targets)
| +- 1.2.5 Check therapeutic antibodies (Thera-SAbDab)
|- 1.3 Identify binding sites
+- 1.4 Predict structure (NvidiaNIM_alphafold2/esmfold)
|
Phase 2: Known Ligand Mining
|- ChEMBL bioactivity data
|- GtoPdb interactions
|- Chemical probes (Open Targets)
|- BindingDB affinity data (Ki/IC50/Kd)
|- PubChem BioAssay HTS data (screening hits)
+- SAR analysis from known actives
|
Phase 3: Structure Analysis
|- PDB structures with ligands
|- EMDB cryo-EM structures (for membrane targets)
|- Binding pocket analysis
+- Key interactions
|
Phase 3.5: Docking Validation (NvidiaNIM_diffdock/boltz2)
|- Dock reference inhibitor
+- Validate binding pocket geometry
|
Phase 4: Compound Expansion
|- 4.1-4.3 Similarity/substructure search
+- 4.4 De novo generation (NvidiaNIM_genmol/molmim)
|
Phase 5: ADMET Filtering
|- Physicochemical properties (Lipinski, QED)
|- Bioavailability, toxicity, CYP interactions
+- Structural alerts (PAINS)
|
Phase 6: Candidate Docking & Prioritization
|- Dock all candidates (NvidiaNIM_diffdock/boltz2)
|- Score by docking (40%) + ADMET (30%) + similarity (20%) + novelty (10%)
|- Assess synthesis feasibility
+- Generate final ranked list (top 20)
|
Phase 6.5: Literature Evidence
|- PubMed (peer-reviewed SAR studies)
|- EuropePMC preprints (source='PPR')
+- OpenAlex citation analysis
|
Phase 7: Report Synthesis & Delivery
CRITICAL : Verify tool parameters before calling unfamiliar tools.
tool_info = tu.tools.get_tool_info(tool_name="ChEMBL_get_target_activities")
| Tool | WRONG Parameter | CORRECT Parameter |
|---|---|---|
OpenTargets_* | ensembl_id | ensemblId (camelCase) |
ChEMBL_get_target_activities | chembl_target_id | target_chembl_id |
ChEMBL_search_similar_molecules |
Resolve all IDs upfront and store for downstream queries:
1. UniProt_search(query=target_name, organism="human") -> UniProt accession
2. MyGene_query_genes(q=gene_symbol, species="human") -> Ensembl gene ID
3. ChEMBL_search_targets(query=target_name, organism="Homo sapiens") -> ChEMBL target ID
4. GtoPdb_get_targets(query=target_name) -> GtoPdb ID (if GPCR/channel/enzyme)
Use multi-source triangulation:
OpenTargets_get_target_tractability_by_ensemblID(ensemblId) - tractability bucketDGIdb_get_gene_druggability(genes=[gene_symbol]) - druggability categoriesOpenTargets_get_target_classes_by_ensemblID(ensemblId) - target classGPCRdb_get_protein + GPCRdb_get_ligands + GPCRdb_get_structuresTheraSAbDab_search_by_target(target=target_name)Decision Point : If druggability < 2 stars, warn user about challenges.
ChEMBL_search_binding_sites(target_chembl_id)get_binding_affinity_by_pdb_id(pdb_id) for co-crystallized ligandsInterPro_get_protein_domains(accession) for domain architectureRequires NVIDIA_API_KEY. Two options:
NvidiaNIM_alphafold2(sequence, algorithm="mmseqs2") - high accuracy, 5-15 minNvidiaNIM_esmfold(sequence) - fast (~30s), max 1024 AAAlways report pLDDT confidence scores (>=90 very high, 70-90 confident, <70 caution).
| Source | Tool | Strengths |
|---|---|---|
| ChEMBL | ChEMBL_get_target_activities | Curated, SAR-ready |
| BindingDB | BindingDB_get_ligands_by_uniprot | Direct Ki/Kd, literature links |
| GtoPdb | GtoPdb_get_target_interactions | Pharmacology focus (GPCRs, channels) |
| PubChem | PubChem_search_assays_by_target_gene | HTS screens, novel scaffolds |
| Open Targets | OpenTargets_get_chemical_probes_by_target_ensemblID |
ChEMBL_get_moleculeBindingDB_get_targets_by_compoundPDB_search_similar_structures(query=uniprot, type="sequence") - find PDB entriesget_protein_metadata_by_pdb_id(pdb_id) - resolution, methodget_binding_affinity_by_pdb_id(pdb_id) - co-crystal ligand affinitiesget_ligand_smiles_by_chem_comp_id(chem_comp_id) - ligand SMILES from PDBemdb_search(query) - cryo-EM structures (prefer for GPCRs, ion channels)alphafold_get_prediction(accession) - AlphaFold DB fallback| Situation | Tool | Input |
|---|---|---|
| Have PDB + SDF | NvidiaNIM_diffdock | protein=PDB, ligand=SDF, num_poses=10 |
| Have sequence + SMILES | NvidiaNIM_boltz2 | polymers=[...], ligands=[...] |
Dock a known reference inhibitor first to validate the binding pocket.
Use 3-5 diverse actives as seeds, similarity threshold 70-85%:
ChEMBL_search_similar_molecules(molecule=SMILES, similarity=70)PubChem_search_compounds_by_similarity(smiles, threshold=0.7)ChEMBL_search_substructure(smiles=core_scaffold)STITCH_get_chemical_protein_interactions(identifier=gene, species=9606)GenMol - scaffold hopping with masked regions:
NvidiaNIM_genmol(smiles="...core...[*{3-8}]...tail...[*{1-3}]...", num_molecules=100, temperature=2.0, scoring="QED")
Mask syntax: [*{min-max}] specifies atom count range.
MolMIM - controlled analog generation:
NvidiaNIM_molmim(smi=reference_smiles, num_molecules=50, algorithm="CMA-ES")
Apply filters sequentially (all take smiles=[list]):
| Step | Tool | Filter Criteria |
|---|---|---|
| Physicochemical | ADMETAI_predict_physicochemical_properties | Lipinski <= 1, QED > 0.3, MW 200-600 |
| Bioavailability | ADMETAI_predict_bioavailability | Oral bioavailability > 0.3 |
| Toxicity | ADMETAI_predict_toxicity | AMES < 0.5, hERG < 0.5, DILI < 0.5 |
| CYP | ADMETAI_predict_CYP_interactions | Flag CYP3A4 inhibitors |
| Alerts | ChEMBL_search_compound_structural_alerts |
Include a filter funnel table in the report showing pass/fail counts at each stage.
| Dimension | Weight | Source |
|---|---|---|
| Docking confidence | 40% | NvidiaNIM_diffdock/boltz2 |
| ADMET score | 30% | ADMETAI predictions |
| Similarity to known active | 20% | Tanimoto coefficient |
| Novelty | 10% | Not in ChEMBL + novel scaffold bonus |
| Tier | Criteria |
|---|---|
| T0 (4 stars) | Docking score > reference inhibitor |
| T1 (3 stars) | Experimental IC50/Ki < 100 nM |
| T2 (2 stars) | Docking within 5% of reference OR IC50 100-1000 nM |
| T3 (1 star) | >80% similarity to T1 compound |
| T4 (0 stars) | 70-80% similarity, scaffold match |
| T5 (empty) | Generated molecule, ADMET-passed, no docking |
Deliver top 20 candidates with: Rank, ID, SMILES, Docking score, ADMET score, overall score, source, evidence tier.
PubMed_search_articles(query="[TARGET] inhibitor SAR") - peer-reviewedEuropePMC_search_articles(query, source="PPR") - preprints (not peer-reviewed)openalex_search_works(query) - citation analysisTarget ID: ChEMBL_search_targets -> GtoPdb_get_targets -> "Not in databases"
Druggability: OpenTargets tractability -> DGIdb druggability -> target class proxy
Bioactivity: ChEMBL -> BindingDB -> GtoPdb -> PubChem BioAssay -> "No data"
Structure: PDB -> EMDB (membrane) -> NvidiaNIM_alphafold2 -> NvidiaNIM_esmfold -> AlphaFold DB -> "None"
Similarity: ChEMBL similar -> PubChem similar -> "Search failed"
Docking: NvidiaNIM_diffdock -> NvidiaNIM_boltz2 -> similarity-based scoring
Generation: NvidiaNIM_genmol -> NvidiaNIM_molmim -> similarity search only
Literature: PubMed -> EuropePMC (preprints) -> OpenAlex
GPCR data: GPCRdb_get_protein -> GtoPdb_get_targets
| Tool | Runtime | Notes |
|---|---|---|
NvidiaNIM_alphafold2 | 5-15 min | Async, max ~2000 AA |
NvidiaNIM_esmfold | ~30 sec | Max 1024 AA |
NvidiaNIM_diffdock | ~1-2 min | Per ligand |
NvidiaNIM_boltz2 | ~2-5 min | End-to-end complex |
NvidiaNIM_genmol | ~1-3 min |
Always check: import os; nvidia_available = bool(os.environ.get("NVIDIA_API_KEY"))
| Database | Limit | Strategy |
|---|---|---|
| ChEMBL | ~10 req/sec | Batch queries |
| PubChem | ~5 req/sec | Batch endpoints |
| ADMET-AI | No strict limit | Batch SMILES in lists |
| NVIDIA NIM | API key quota | Cache results |
For large expansions (>500 compounds): batch in chunks of 100, prioritize top candidates for docking.
For detailed protocols, examples, and templates, see:
| File | Contents |
|---|---|
| WORKFLOW_DETAILS.md | Phase-by-phase procedures, code patterns, screening protocols, fallback chain details |
| TOOLS_REFERENCE.md | Complete tool reference with parameters, usage examples, and fallback chains |
| REPORT_TEMPLATE.md | Report file template, evidence grading system, section formatting examples |
| EXAMPLES.md | End-to-end workflow examples (EGFR, novel target, lead optimization, NVIDIA NIM) |
| CHECKLIST.md | Pre-delivery verification checklist for report quality |
Weekly Installs
146
Repository
GitHub Stars
1.2K
First Seen
Feb 7, 2026
Security Audits
Gen Agent Trust HubPassSocketPassSnykWarn
Installed on
gemini-cli137
codex137
opencode137
github-copilot134
kimi-cli129
amp129
AI 代码实施计划编写技能 | 自动化开发任务分解与 TDD 流程规划工具
50,900 周安装
LiteParse 本地文档解析工具 - 快速解析PDF/DOCX/PPTX/XLSX/图像,无需云依赖
734 周安装
交易策略回测框架:8种内置策略、性能指标与参数优化
738 周安装
社交媒体营销专家指南:Instagram、TikTok、LinkedIn平台策略与内容创作优化
737 周安装
Semantic Kernel 开发指南:AI 集成与函数调用最佳实践(C#/.NET 与 Python)
759 周安装
DeepWiki MCP 服务器:AI 驱动的 GitHub 仓库文档搜索与问答工具
741 周安装
Nx Plugins 插件库 - 查找安装 Nx 插件,提升开发效率与项目架构
752 周安装
smilesmolecule (accepts SMILES, ChEMBL ID, or name) |
alphafold_get_prediction | uniprot | accession |
ADMETAI_* | smiles="..." | smiles=["..."] (must be list) |
NvidiaNIM_alphafold2 | seq | sequence |
NvidiaNIM_genmol | smiles="C..." | smiles="C...[*{1-3}]..." (must have mask) |
NvidiaNIM_boltz2 | sequence="..." | polymers=[{"molecule_type": "protein", "sequence": "..."}] |
| Validated probes |
| No PAINS |
| Depends on num_molecules |
NvidiaNIM_molmim | ~1-2 min | Close analog generation |